Compare Citius Pharmaceuticals Inc (CTXR) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs SkyWest Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while SkyWest Inc trades at $100.14 (market cap $3.85B). The key difference: SkyWest Inc is far larger — about 263× Citius Pharmaceuticals Inc's market cap, and SkyWest Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | SKYW | |
|---|---|---|
Market Cap | $14.64M | $3.85B |
Sector | Health | Technology |
52-Week High | $1.82 | $123.72 |
52-Week Low | $0.53 | $78.40 |
Enterprise Value | $10.86M | $5.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
SkyWest (SKYW) trades at $97.78, down 1.95% on the day, with a bullish technical signal from moving averages and a neutral RSI. The stock shows strong fundamentals with a P/E of 9.32 and net income margin of 10.42%, supported by recent earnings beats. Analyst consensus is bullish with a $109.33 price target. Recent news includes a key executive appointment and attention to fuel cost pressures in the airline industry.
The outlook for SKYW is positive given its attractive valuation and profitability, but risks include rising fuel expenses and industry volatility. With no sell ratings and 56% buy consensus, the stock presents a compelling opportunity for upside, though investors should monitor cost management and quarterly results closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
